| Country (WHO classification) | Estimated HIV+ TB cases# n | Estimated MDR-TB among notified TB cases# n | Total MDR cases that are new TB cases#,¶ % | Xpert policy | Cartridges procured§ n | Smear/Xpert cartridge ratioƒ | Modules procured§ n | Availability in private sector | Algorithm | SLT initiation | |
| Patients with high risk of DR | Patients with low risk of DR | ||||||||||
| Afghanistan | 310 | 1150 | 65 | N | 570 (460) | 37.0 | 6 | N | DR | Treat w/DST | Treat w/ DST |
| Bangladesh (HDR) | 240 | 4200 | 45 | Y | 114 910 (96 300) | 15.0 | 376 | Y w/PPM | DR | Treat no DST | Treat w/ DST |
| Brazil (HTH) | 16 000 | 1710 | 50 | Y | 290 930 (256 670) | 6.2 | 716 | Y w/o PPM | All EPTB Children | Under revision | |
| Cambodia (HTH) | 2700 | 386 | 85 | Y | 57 640 (20 690) | 21.1 | 96 | N | DR HIV+ | Treat w/DST | Wait |
| China (HDR, HTH) | 7300 | 60 000 | 82 | Y | 240 000 (227 560) | 74.3 | 3812 | Y w/o PPM | DR | Treat no DST | Wait |
| DR Congo (HDR, HTH) | 16 000 | 2860 | 73 | Y | 67 740 (24 780) | 31.2 | 110 | N | DR HIV+ | Treat w/DST | Treat w/DST |
| Ethiopia (HDR, HTH) | 23 000 | 2080 | 77 | Y | 37 040 (12 680) | 378.5 | 104 | Y w/o PPM | DR HIV+ Children | Treat no DST | Treat w/o DST |
| India (HDR, HTH) | 130 000 | 64 000 | 33 | Y | 379 200 (232 150) | 71.5 | 598 | Y w/PPM | DR HIV+ Children | Treat w/DST | Wait |
| Indonesia (HDR, HTH) | 7500 | 6800 | 85 | Y | 52 950 (41 250) | 39.3 | 284 | Y w/PPM | DR HIV+ | Treat w/DST | Wait |
| Kenya (HTH) | 45 000 | 2780 | 65 | Y | 147 950 (81 010) | 47.6 | 370 | Y w/PPM | DR HIV+ Children | Treat w/DST | Wait |
| Mozambique (HTH) | 83 000 | 1940 | 72 | Y | 76 020 (31 700) | 6.2 | 108 | N | DR HIV+ Children | Treat w/DST | Treat w/DST |
| Myanmar (HDR, HTH) | 19 000 | 6100 | 80 | Y | 72 520 (40 100) | 23.2 | 164 | N | DR HIV+ Children | Wait | Wait |
| Nigeria (HDR, HTH) | 46 000 | 3600 | 69 | Y | 76 840 (38 080) | 27.8 | 400 | Y w/PPM | DR HIV+ EPTB | Wait | Wait |
| Pakistan (HDR) | 3800 | 11 400 | 68 | Y | 98 200 (45 860) | 31.0 | 294 | Y w/PPM | DR HIV+ EPTB | Treat w/DST | Wait for 2nd Xpert |
| Philippines (HDR) | 460 | 15 300 | 55 | Y | 71 780 (34 350) | 41.9 | 404 | Y w/PPM | DR HIV+ EPTB Children | Wait | Wait |
| Russia (HDR, HTH) | 9300 | 45 000 | 44 | N | 15 490 (2 950) | 2386.4 | 58 | N | All | Treat w/DST | Treat w/DST |
| South Africa (HDR, HTH) | 330 000 | 8100 | 43 | Y | 4 228 480 (2 312 280) | 1.6 | 4132 | Y w/o PPM | ALL EPTB Children | Treat w/DST | Wait |
| Tanzania | 32 000 | 500 | 100 | Y | 113 550 (56 640) | 12.0 | 192 | N | DR, Unknown HIV+ Children | Treat w/o DST | Wait |
| Thailand (HTH) | 12 000 | 1760 | 45 | Y | 24 560 (10 330) | 123.9 | 85 | Y w/o PPM | DR HIV+ (smear−) | Treat w/DST | Wait |
| Uganda (HTH) | 35 000 | 1010 | 53 | Y | 84 560 (50 340) | 4.1 | 266 | N | DR HIV+ (smear−) | Treat w/ or w/o DST## | Wait |
| Vietnam (HDR, HTH) | 9300 | 3800 | 55 | Y | 54 930 (31 130) | 62.6 | 158 | Y w/o PPM | DR HIV+ Children | Treat w/DST | Wait |
| Zimbabwe (HTH) | 55 000 | 930 | 61 | Y | 146 340 (83 590) | 0.6 | 300 | N | DR Unknown HIV+ Children | Under revision | |
WHO: World Health Organization; MDR: multidrug-resistant; SLT: second-line treatment; DR: drug resistance; HDR: high MDR-TB burden; HTH: high TB/HIV burden; N: no; Y: yes; PPM: private–public mix initiatives (initiatives encouraged by WHO to promote the collaboration between private and public health providers in the delivery of TB care); EPTB: extrapulmonary TB HIV+ (smear−): HIV+ patients presumed to have TB but with a negative smear; DST: drug susceptibility testing; wait: do not start until DR is confirmed. #: in 2012 [1]. ¶: rather than retreatment TB patients. §: accumulated procurement until June 30, 2014 (and the accumulated procurement in the past 12 months) [4], under concessional pricing; the data do not include private sector procurement. ƒ: ratio of the numbers of smears performed in high-burden countries for initial diagnosis to the numbers of Xpert cartridges procured in the same country; the annual smear volumes were collected for the year 2012 [5], the numbers of Xpert cartridges procured were for the last 12 months (July 2013 to June 2014). ##: in Uganda, DR-TB contacts with TB symptoms require no confirmation before initiating SLT (w/o DST), while the other Xpert RIF-resistant patients suspected to have DR-TB will start on SLT with confirmatory DST.